A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1

British Journal of Ophthalmology

Volumn 99, Issue 7, 2015, Pages 954-959

  Narayanan, Raja ^a   Panchal, Bhavik ^a   Das, Taraprasad ^a   Chhablani, Jay ^a   Jalali, Subhadra ^a   Hasnat Ali, M ^a   Balakrishnan, Divya ^b   Bandi, Navakanth ^b   Bansal, Piyush ^b   Dave, Vivek ^b   Kamath, Sripathi ^b   Kumar, Kshitiz ^b   Majji, Ajit B ^b   Mathai, Annie ^b   Mithal, Kopal ^b   Kolawale, Olubayo ^b   Partani, Anand ^b   Phalak, Devendra ^b   Rani, Padmaja K ^b   Reddy, Rajeev P ^b   Relhan, Nidhi ^b   Sudhalkar, Aditya ^b   Tyagi, Mudit ^b   Venkatramani, Devendra ^b   Bhargava, Archana ^b   Rayasam, Sridevi ^b   more..

^a L V PRASAD EYE INSTITUTE   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINAL THICKNESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA NEOVASCULARIZATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PHYSIOLOGY; RETINA VEIN OCCLUSION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84937738744     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-306543     Document Type: Article

References (18)

1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82.
2. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28.
3. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12 e1.
4. Stein JD, Newman-Casey PA, Kim DD, et al. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013;120:1835-42.
5. Stein JD, Newman-Casey PA, Mrinalini T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121:936-45.
6. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
7. Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
8. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013;156:502-10 e2.
9. Niederhauser N, Valmaggia C. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions]. Klin Monbl Augenheilkd 2013;230:405-8.
10. Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013;1:CD009510.
11. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 2003;135:194-205.
12. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-5.
13. Donati S, Barosi P, Bianchi M, et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 2012;22:607-14.
14. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina 2011;31:1856-62.
15. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-6.
16. Thach AB, Yau L, Hoang C, et al. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 2014;121:1059-66.
17. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86 e2.
18. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-602.